A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Systemic sclerosis (scleroderma) is an autoimmune connective tissue disease that involves the
skin and other internal organs for which there are few effective treatment options. We
hypothesize that treatment with abatacept, a new therapy recently approved for the treatment
of rheumatoid arthritis, may reduce the progression of skin thickening and fibrosis in people
with scleroderma.